Treatment failure with rituximab in a patient with pemphigus vulgaris [18]

Journal of the European Academy of Dermatology and Venereology

Volumn 22, Issue 3, 2008, Pages 387-389

  Weger, W ^a   Aberer, Elisabeth ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHLOROQUINE; CYCLOPHOSPHAMIDE; DAPSONE; DOXYCYCLINE; NICOTINAMIDE; PREDNISOLONE; RITUXIMAB;

AGED; CASE REPORT; CLINICAL PROTOCOL; DISEASE COURSE; DISEASE SEVERITY; DRUG TREATMENT FAILURE; FOLLOW UP; GINGIVITIS; HUMAN; LETTER; MALE; MOUTH ULCER; PEMPHIGUS VULGARIS; PERIODONTITIS; PRIORITY JOURNAL; REMISSION; TREATMENT OUTCOME;

AGED; ANTI-INFECTIVE AGENTS; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; DAPSONE; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; MALE; PEMPHIGUS; PREDNISOLONE; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 39049118724     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2007.02340.x     Document Type: Letter

References (10)

1. Arin MJ, Hunzelmann N. Anti-B-cell-directed immunotherapy (rituximab) in the treatment of refractory pemphigus -an update. Eur J Dermatol 2005; 15: 224-230.
2. El Tal AK, Posner MR, Spigelman Z, Ahmed AR. Rituximab: A monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris. J Am Acad Dermatol 2006; 55: 449-459.
3. Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 2006; 355: 1772-1779.
4. Schmidt E, Seitz CS, Benoit S, Bröcker EB, Goebeler M. Rituximab in autoimmune bullous diseases: Mixed responses and adverse effects. Br J Dermatol 2007; 156: 352-356.
5. Niedermeier A, Wörl P, Barth S, Schuler G, Hertl M. Delayed response of oral pemphigus vulgaris to rituximab treatment. Eur J Dermatol 2006; 16: 266-270.
6. Cartron G, Dacheux L, Salles G et. al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99: 754-758.
7. McHeyzer-Williams MG, Ahmed R. B cell memory and the long-lived plasma cell. Curr Opin Immunol 1999; 11: 172-179.
8. Anolik JH, Campbell D, Felgar RE et. al. The relationship of FcγRIIIa genotype to the degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 2003; 48: 455-459.
9. Leandro MJ, Edwards JCW, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 2002; 61: 883-888.
10. Rose AL, Smith BE, Maloney DG. Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects. Blood 2002; 100: 1765-1773.